Chemotherapy probably leads to higher progression‐free survival compared with biological therapy (moderate certainty).
It is very uncertain whether chemmotherapy combined with biological therapy changes progression‐free survival compared with chemotherapy (very low certainty).
Chemotherapy leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).
Biological therapy probably leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
Irinotecan leads to lower progression‐free survival compared with non‐irinotecan‐containing regimens (high certainty).
Docetaxel probably leads to lower progression‐free survival compared with non‐docetaxel‐containing regimens (moderate certainty).
It is very uncertain whether capecitabine changes progression‐free survival compared with 5‐FU‐containing regimens (very low certainty).
Oxaliplatin showed no clear difference in progression‐free survival compared with the same regimen including cisplatin (low certainty).
Taxane‐platinum‐fluoropyrimidine combinations probably leads to lower progression‐free survival compared with taxane‐platinum (without fluoropyrimidine) (moderate certainty).
S‐1 showed no clear difference in progression‐free survival compared with 5‐FU‐containing regimens (low certainty).
Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).
It is very uncertain whether docetaxel changes progression‐free survival ‐ Substitutive comparisons compared with non‐docetaxel‐containing regimens (very low certainty).
Irinotecan showed no clear difference in progression‐free survival ‐ Substitutive comparison compared with non‐irinotecan‐containing regimens (moderate certainty).
Chemotherapy showed no clear difference in progression‐free survival (non‐taxane monotherapy vs taxane… compared with chemotherapy (low certainty).